Dong, Qiuju <br/><br/>
PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.  [electronic resource] 

 -  Scientific reports  04 2019 
 - 5692 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-019-42245-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Line, Tumor<br/>ErbB Receptors--genetics<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Mutation<br/>Piperazines--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Receptor, ErbB-2--genetics<br/>Receptor, ErbB-4--genetics<br/>Signal Transduction<br/>Xenograft Model Antitumor Assays